Sa1612 70% Liver Resection in Rats. Pentadecapeptide BPC 157, L-Arginine, L-NAME: BPC 157 Beneficial Effect Counteracts Worsening Induced by L-NAME

BACKGROUND: Chronic liver disease and cirrhosis are becoming a national public health concern, due to progressively rising rates of morbidity and mortality.It is pivotal to recognize liver compromise.The liver has an essential role in lipid synthesis and transportation.It is reasonable to assume that patients with advanced fibrosis and cirrhosis will have lipid derangements.It has been postulated in past studies that certain values within the lipid profile change, yet there is very limited supporting data on biopsy proven samples.METHODS: We conducted a multi-center retrospective observational study on 280 patients who had biopsy proven liver disease.In order to avoid confounders we excluded patients on statins.A propensity score matching was used to select the patients with similar demographics in each stage of fibrosis (Stages 1 to 4, using the Batts and Ludwig model).Finally, 23 patients in each stage were matched and evaluated.Mean, standard deviation and range were used to describe the distributions of serum markers in different fibrosis stages.Analysis of Variance (ANOVA) were used to compare lipid panel among fibrosis stages.P<0.05 was considered as being of statistical significance.Total cholesterol (N<200), triglycerides (N<150), LDL (N<130), HDL (N>40), Non-HDL (N<130), and VLDL (N=10 to 50) were extracted from each patient.RESULTS: Total cholesterol, HDL, LDL, and Non-HDL decreased progressively after stage 2 fibrosis, most significantly when going from stage 3 to stage 4. 23 patients with stage 1 fibrosis had the following average values: total cholesterol (181.2),TG(166.5),LDL (105), HDL (48.2), and VLDL (25.9).23 patients with stage 2 fibrosis had the following average values: total cholesterol (197), TG (135.4),LDL (112.8),HDL(52), and VLDL (27.1).23 patients with stage 3 fibrosis had the following average values: total cholesterol (176.9),TG (141.7),LDL (102.7),HDL (50.8), and VLDL (28.3).23 patients with stage 4 fibrosis had the following average values: total cholesterol (154), TG (133.6),LDL (84.7),HDL (41.4), and VLDL (26.7).CONCLUSION: This is the first large multi-center study done on biopsy proven samples comparing lipid panel directly with stages of fibrosis.Herein we conclude; the lipid panel has an inverse relationship when compared with worsening liver disease measured as progression of fibrosis.It is important to recognize a decrease in these lipid panel values, although they remain within normal laboratory range, suggests worsening liver disease.